These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 26846397)

  • 1. Comment on "Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis": By Pscherer S et al. published in Prim. Care Diabetes 2015 Oct;9(5):377-84.
    Kalra S
    Prim Care Diabetes; 2016 Aug; 10(4):309-10. PubMed ID: 26846397
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147.
    Home PD
    Diabetes Care; 2013 Jul; 36(7):e106. PubMed ID: 23801808
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147.
    Bergenstal RM; Rosenstock J; Arakaki RF; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
    Diabetes Care; 2013 Jul; 36(7):e107-8. PubMed ID: 23801809
    [No Abstract]   [Full Text] [Related]  

  • 4. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
    Oliveira JH; Kazda C; Simpson A; Jackson JA; Heine RJ
    Lancet; 2008 Aug; 372(9636):371-2; author reply 372. PubMed ID: 18675683
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetes injectable therapy: type 2 diabetes management in Danish practice.
    Sterzi D; Auziere S; Jensen MM; Lopes S
    Curr Med Res Opin; 2017 Dec; 33(12):2211-2216. PubMed ID: 28875722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus.
    Polonsky W; Traylor L; Wei W; Shi R; Ameer B; Vlajnic A; Nicolucci A
    Diabetes Obes Metab; 2014 Mar; 16(3):255-61. PubMed ID: 24028669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiating insulin in primary care--the role of modern premixed formulations.
    Ligthelm R; Davidson J
    Prim Care Diabetes; 2008 Feb; 2(1):9-16. PubMed ID: 18684415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.
    Ross S; Dzida G; Ji Q; Kaiser M; Ligthelm R; Meneghini L; Nazeri A; Orozco-Beltran D; Pan C; Svendsen AL;
    J Diabetes; 2014 May; 6(3):243-50. PubMed ID: 24103141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
    Lajara R; Cengiz E; Tanenberg RJ
    Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comment on Home et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes care 2014;37:1499-1508.
    Conget I; Aronson R; Lee S; Cohen O; Reznik Y
    Diabetes Care; 2014 Nov; 37(11):e245-6. PubMed ID: 25342842
    [No Abstract]   [Full Text] [Related]  

  • 12. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
    Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
    Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
    Khunti K; Cos X; Rutten G
    Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
    Berard L; MacNeill G
    Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
    Muñoz Torres M
    Endocrinol Nutr; 2014 Mar; 61(3):153-9. PubMed ID: 23890782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
    Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
    Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs.
    Dungan KM; Buse JB; Herman WH; Arakaki RF; Jiang HH; Jacobson JG; Fahrbach JL
    Diabetes Res Clin Pract; 2012 Jun; 96(3):e66-9. PubMed ID: 22421598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential effect of ultra-long insulin degludec on glycemic variability.
    Rodacki M; Carvalho RM; Zajdenverg L
    Diabetes Res Clin Pract; 2017 Nov; 133():92-103. PubMed ID: 28918342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for initiating insulin in type 2 diabetes.
    Korownyk C; Ivers N; Allan GM
    Can Fam Physician; 2011 May; 57(5):562. PubMed ID: 21571718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.